Rep. Robert Bresnahan, Jr. Sells Off Shares of Teleflex Incorporated (NYSE:TFX)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Teleflex Incorporated (NYSE:TFX). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in Teleflex stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Teleflex Stock Down 1.2 %

Shares of NYSE TFX opened at $137.76 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. Teleflex Incorporated has a 1 year low of $128.55 and a 1 year high of $249.91. The company has a 50 day simple moving average of $159.20 and a 200 day simple moving average of $190.36. The firm has a market cap of $6.39 billion, a PE ratio of 27.39, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, topping analysts’ consensus estimates of $3.86 by $0.03. The company had revenue of $795.40 million for the quarter, compared to analyst estimates of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. On average, research analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, March 7th were issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.99%. The ex-dividend date of this dividend was Friday, March 7th. Teleflex’s dividend payout ratio (DPR) is currently 95.77%.

Analyst Upgrades and Downgrades

TFX has been the topic of a number of recent analyst reports. Truist Financial cut their price objective on Teleflex from $200.00 to $149.00 and set a “hold” rating on the stock in a research note on Monday, March 3rd. StockNews.com downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Morgan Stanley decreased their price objective on shares of Teleflex from $275.00 to $191.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Wells Fargo & Company dropped their target price on shares of Teleflex from $214.00 to $146.00 and set an “equal weight” rating on the stock in a report on Friday, February 28th. Finally, Raymond James downgraded Teleflex from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Teleflex has a consensus rating of “Hold” and an average target price of $182.63.

Institutional Trading of Teleflex

Large investors have recently made changes to their positions in the company. Headlands Technologies LLC bought a new position in Teleflex in the fourth quarter worth approximately $29,000. True Wealth Design LLC grew its position in Teleflex by 16,600.0% in the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock valued at $41,000 after purchasing an additional 166 shares during the period. Avior Wealth Management LLC increased its stake in Teleflex by 81.2% during the 4th quarter. Avior Wealth Management LLC now owns 279 shares of the medical technology company’s stock valued at $50,000 after purchasing an additional 125 shares in the last quarter. IFP Advisors Inc raised its holdings in Teleflex by 238.5% during the fourth quarter. IFP Advisors Inc now owns 308 shares of the medical technology company’s stock worth $55,000 after buying an additional 217 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Teleflex by 38.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 340 shares of the medical technology company’s stock valued at $61,000 after buying an additional 94 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.